Latest Bubs Australia (ASX:BUB) News

Bubs Australia has submitted critical clinical trial data to the US FDA, marking a pivotal step toward permanent approval for its infant formulas in the US market.

Bubs Australia has triumphed in a long-standing legal dispute, winning $26.5 million in arbitration awards against Alpha Group subsidiaries Alice Trading and Willis Trading. The company now faces the challenge of recovering the awarded sums.

Bubs Australia has reported a strong Q2 FY25 performance with a positive EBITDA turnaround and robust revenue growth, while advancing its critical FDA clinical trial in the US.